Researchers at the Icahn School of Medicine have unveiled the AMETA Nanobody Platform, which effectively combats SARS-CoV-2 and other rapidly mutating viruses.
This new antibody approach utilizes engineered nanobodies targeting multiple stable virus regions, enhancing binding strength and resistance to mutations. The platform offers potential for broader infectious disease management, including HIV and influenza, with promising preclinical outcomes.
AMETA Nanobody Platform
Scientists at the Icahn School of Medicine at Mount Sinai, working with experts in the field, have developed a groundbreaking antibody platform designed to address a major challenge in treating rapidly evolving viruses like SARS-CoV-2: their ability to mutate and resist current vaccines and treatments.
Their research, including preclinical studies in mice, introduces the Adaptive Multi-Epitope Targeting and Avidity-Enhanced (AMETA) Nanobody Platform. This innovative approach targets how viruses such as SARS-CoV-2, the virus responsible for COVID-19, mutate to escape existing therapies. The results of their study were published today (October 23) in the journal Cell.
The Challenge of Rapid Viral Evolution
Since the start of the COVID-19 pandemic, SARS-CoV-2 has quickly mutated, making many vaccines and treatments less effective. To combat this, Yi Shi, PhD, and his team at Icahn Mount Sinai created AMETA, a versatile platform that uses engineered nanobodies to simultaneously target multiple stable regions of the virus that are less likely to mutate. This multi-targeting strategy, paired with a significant boost in binding strength, provides a more durable and resilient defense against evolving viruses, say the researchers.
“Mutational escape in SARS-CoV-2 has been a persistent challenge, with current vaccines and treatments struggling to keep pace with the virus’s rapid evolution,” says Dr. Shi, lead corresponding author and Associate Professor of Pharmacological Sciences at Icahn Mount Sinai. “Most therapeutic antibodies target a single viral site and lose effectiveness within a year as new variants appear. AMETA, however, is designed to bind to multiple conserved regions of the virus at once, making it much harder for resistance to develop. This platform can potentially be adapted for other fast-mutating pathogens, offering a durable and adaptable approach to managing infectious diseases globally.”
Mechanisms and Efficacy of AMETA
AMETA is designed by attaching specialized nanobodies to a human IgM scaffold, which is a part of the immune system’s natural defense structure that helps fight infections. This allows AMETA to display more than 20 nanobodies at once, significantly boosting its ability to bind to the virus by targeting multiple stable regions on its surface, say the investigators. As a result, AMETA is far more effective against advanced variants, offering up to a million times greater potency compared to traditional antibodies that focus on a single target.
Both lab tests and experiments in mice have shown that AMETA constructs are highly effective against a range of SARS-CoV-2 variants, including the heavily mutated Omicron sublineages and even the closely related SARS-CoV virus, according to the investigators. Collaborating with researchers from the University of Oxford and Case Western Reserve University, the team used advanced imaging tools like cryo-electron microscopy and cryotomography to reveal that AMETA neutralizes the virus through several unexpected mechanisms. These include clumping viral particles together, binding to key regions of the spike protein, and disrupting the spike’s structure in ways not seen in other antiviral treatments, preventing the virus from infecting cells.
AMETA’s Future Applications in Disease Management
“Our goal with AMETA is to create a long-lasting platform that overcomes the fast-evolving properties of viral pathogens,” says Adolfo Garcia-Sastre, PhD, co-senior author of the study, Irene and Dr. Arthur M. Fishberg Professor of Medicine, and Director of the Global Health and Emerging Pathogens Institute at Icahn Mount Sinai. “This platform is not just a solution for COVID-19 but could also serve as a framework for combating other rapidly mutating human microbes, like HIV, and for protection from future emerging viruses, including influenza viruses with pandemic potential.”
“AMETA’s flexible design allows it to be quickly adapted to target a diverse range of pathogens, providing an agile and dynamic solution for emerging infections. Our findings represent a major step forward in overcoming mutational escape across viruses and antibiotic-resistant microbes,” adds Dr. Shi.
Preparing for Wider AMETA Trials
With its modular structure, AMETA also enables rapid and cost-effective production of new nanobody constructs, making it an ideal candidate for addressing future pandemics, say the investigators.
Drs. Shi and Garcia-Sastre’s teams are now preparing for additional preclinical and potential clinical trials to evaluate AMETA’s therapeutic potential across various diseases.
Reference: “Adaptive multi-epitope targeting and avidity-enhanced nanobody platform for ultrapotent, durable antiviral therapy” by Yufei Xiang, Jialu Xu, Briana L. McGovern, Anna Ranzenigo, Wei Huang, Zhe Sang, Juan Shen, Randy Diaz-tapia, Ngoc Dung Pham, Abraham J.P. Teunissen, M. Luis Rodriguez, Jared Benjamin, Derek J. Taylor, Mandy M.T. van Leent, Kris M. White, Adolfo García-Sastre, Peijun Zhang and Yi Shi, 23 October 2024, Cell.
DOI: 10.1016/j.cell.2024.09.043
The remaining authors of the paper, all with Icahn Mount Sinai except where indicated, are Yufei Xiang, MS; Jialu Xu, PhD (University of Oxford, UK); Briana L. Mcgovern, BS; Anna Ranzenigo, PhD; Wei Huang, PhD (Case Western Reserve University, Cleveland); Zhe Sang (Icahn Mount Sinai PhD student); Juan Shen, PhD (University of Oxford, UK); Randy Diaz-tapia (Touro College of Pharmacy PharmD candidate); Ngoc Dung Pham, PhD; Abraham J.P. Teunissen, PhD; M. Luis Rodriguez, MS; Jared Benjamin, MS; Derek J. Taylor, PhD (Case Western Reserve University, Cleveland); Mandy M.T. van Leent, MD/PhD; Kris M. White, PhD; and Peijun Zhang, PhD (University of Oxford, UK and Diamond Light Source, UK).
The study was supported by funding from the National Institutes of Health through grants R35GM137905, R01AI163011, and R01HL169500, as well as from CRIPT (Center for Research on Influenza Pathogenesis and Transmission), a Center of Excellence for Influenza Research and Response (CEIRR) funded by NIAID (contract #75N93021C00014). Additional support was provided by the Clinical and Translational Science Awards (CTSA) grant UL1TR004419 from the National Center for Advancing Translational Sciences.
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.